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1 For a survey of national systems see Ole Lando & Hugh Beale eds., Principles of European Contract Law: Parts I and II, Kluwer
Law International (2000) 368-370; also Treitel, Remedies, §276. Such is the general case in Common Law, expressed already in
Borrowman, Phillips & Co. v. Free & Hollis, (1878) 4 Q.B.D. 500. See Jacob S. Ziegel, “The Remedial Provisions in the Vienna Sales
Convention: Some Common Law Perspectives” in Galston & Smit (ed.), International Sales: The United Nations Convention on
Contract s  f o r  the  In t e rna t iona l  Sa l e  o f  Goods ,  (Mat thew Bender ,  1984)  pp.  9 -1  to  9 -43,  avai lable online at
<http://cisgw3.law.pace.edu/cisg/biblio/ziegel6.html>. The English Sales of Goods Act does not include a seller’s general right to
cure, while the UCC §2-508 famously does. For elaboration on the position of English law see and Goode, Commercial Law 298-
301; Rex J. Ahdar, “Seller Cure in the Sale of Goods”, 1990 Lloyd’s Mar. Com. L. Q. 364. Other commentators are more skeptical
concerning the availability of post-breach cure under English law; see Anette Gàrtner, “Britain and the CISG: The Case for
Ratification - A Comparative Analysis with Special Reference to German Law” in Review of the Convention on Contracts for the
In t e r na t i o n a l  S a l e  o f  Good s  (C ISG) ,  Kluwer  Law In t e rna t i ona l  ( 2000 -2001 )  59 -81 ,  a va i l ab l e  on l ine  a t
<http://cisgw3.law.pace.edu/cisg/biblio/gartner.html>; see also Sale and Supply of Goods, Law Com. 85, Scot. Law Com. 58 (1983)
para 2.38 according to which “There is great uncertainty, at least in English law, as to the existence and extent of the seller's right
to repair or replace defective goods”.
2 USCA, Title 15, Appendix (Supp. 1987). Since entering into force in 1988, the CISG has been adopted by some 64
countries, representing roughly 2/3 of world international trade. Subject to certain exemptions (See Art. 2) and subject to the
power of the parties to derogate from it (Art. 6), the CISG covers all international sales transaction; in the US, it would substitute
for UCC Art. 2 as well as for non-code law in matters governed by its provisions. For general literature on the CISG see JOHN
HONNOLD, UNIFORM LAW FOR INTERNATIONAL SALES (Kluwer, 1999). A vast and usefully organized source of CISG-related
materials is available on the Pace University website at <http://cisgw3.law.pace.edu/cisg.html>.
3 Concluded (in English) in 2003, the PECL is not a statute or convention nor—yet—a model law, but a scholarly document
produced by an authoritative panel of European jurists under the auspices of the EU (a.k.a. the “Lando Commission” alluding to
its chair). Its purpose is to unify contract law in the several European states and provide interpretative directions. It has been
compared to a restatement of law in its nature and “applies” to all contractual transactions, domestic and transnational. See OLE
LANDO AND HUGH BEALE (EDS.), PRINCIPLES OF EUROPEAN CONTRACT LAW: PARTS I AND II (Kluwer Law International (2000)
(hereinafter “Lando and Beale”). 
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1. General
A contractual party’s right to cure a non-performance under the condition that such cure does not
create any – or at least any excessive – hardship for the aggrieved party, has emerged from
Common Law traditions to become almost a staple of modern contract law, and of modern sales
law in particular.1 This study reviews and analyses the respective provisions governing the seller’s
right to cure under two important legal regimes, that of the UN Convention on Contracts for the
International Sale of Goods, 1980 (hereinafter CISG)2 and the newly drafted Principles of
European Contract Law, 2003 (hereinafter PECL).3 
Different justifications to the principle of cure may be cited, whether in terms of risk allocation,
good faith obligations, or the relational approach to contract as a framework of relations between
parties that shifts the analytic emphasis from overt rules (whether set contractually or by statute)
to the actual framework of relations and interests involved. Be the theoretical overview what it
may, the principle of cure is perhaps the most important deviation from strict doctrines of liability
for breach, and as such it maintains an important relation to the doctrine of contract avoidance
(“termination” in the context of the PECL), as discussed below. 
Curing a non-performance may be relevant in various contexts: payment, defective or missing
documents, non-conforming or non-delivered goods, etc. In the PECL – which apply to any and
all contractual transactions, not only sales or international sales – Art. 8:104 recognizes a non-
performing party’s general right to cure, limited by parameters that will be discussed presently. In
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4 See Jonathan Yovel, “Comparison between provisions of the CISG (Buyer’s right to avoid the contract: Article 49) and the
c o u n t e r p a r t  p r o v i s i o n s  o f  t h e  P E C L  ( A r t i c l e s  9 : 3 0 1 ,  9 : 3 0 3  a n d  8 : 1 0 6 ) ” ,  a v a i l a b l e  o n l i n e  a t
<http://cisgw3.law.pace.edu/cisg/biblio/yovel49.html>.
5 Commentators frequently use “right” and “power” interchangeably. Hohfeld’s analytic language would be useful here
(Hohfeld supplied a Saussurian-style analytic syntax whereby legal concepts are defined through their relation to other concepts):
to claim that A holds a right – properly defined – correlates with B’s duty; A’s liberty correlates with B’s lack of right to object, and
A’s power correlates with B being subject to that power in the sense that using the power would change the normative array of rights,
duties, liberties, powers, subjections, immunities etc. between the parties. Thus the “right to declare the contract avoided” is,
properly speaking, a legal power (it changes the parties’ legal relations), as is the buyer’s power to set a Nachfrist period; but as the
seller’s “right to cure” does not in itself change the relational framework yet does require the buyer to accept the curative tender
it is, properly speaking, a right. Had it required no compliance from the buyer – had it been performed, say, by the seller and a
third party – cure would be, properly speaking, a liberty. See Welsley Hohfeld, Fundamental Legal Conceptions as Applied in Juridical
Reasoning (New Haven: Yale University Press, 1964 [1919]). For an application of the Hohfeldian matrix to the analysis of
contractual relations see Jonathan Yovel, “What is Contract Law ‘About’? Speech Act Theory and a Critique of ‘Skeletal
Promises’”, 94 Northwestern U. Law Rev. (2000) 937-962. 
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the CISG – divided as it is into seller’s and buyer’s rights and obligations – the right to cure non-
performance depends upon the nature of the non-performance and the time of cure, and is
divided into different typical situations, covered by several articles. Some grant parties the right to
cure defective performance prior to the time of the projected performance as contracted: in those
cases, cure limits aggrieved parties’ power to declare contracts avoided in situations of anticipatory
breach. Thus, Art. 34 relates to curing defective or non-conforming documents, and Art. 37 deals
with breach in respect to goods. Other articles refer to the aggrieved party’s power to require
curative performance, such as Art. 46(2) and (3). These are relatively non-controversial issues, and
one may argue that refusal to allow cure prior to the time set for performance is ad definitio a
breach of good faith obligations. Indeed, the true meaning of cure pertains to a defaulting party’s
right to cure a defective performance or non-performance after the time of the projected
performance has passed. Thus this commentary deals with the seller’s right to cure under CISG
Art. 48 and PECL Art 8:104, which extend the right to cure once the fact of breach has been
established.
Although both the PECL and CISG recognize a right to cure under certain conditions, they differ
both in general approach as well as in the specific rights granted. This may not be surprising, as
the PECL applies to any and all contractual transactions, not only sales or international sales;
however, the seller’s right to cure is closely related to the buyer’s right to avoid the contract, an
issue on which the CISG and PECL share similar approaches.4 Indeed, the relation between cure
and avoidance must be a central topic for analysis once the nature of the right to cure has been
clarified.
2. The Jurisprudential Nature of the Right to Cure
One must distinguish between a breaching party’s general (or unqualified) right to cure and a
qualified right. A general right means that within certain timeframe constraints and other objective
constraints, the breaching party may exercise the right unilaterally, independent of anything the
aggrieved party may do in respect to the breach. A qualified right means that the breaching party’s
right to cure a non-performance depends upon the aggrieved party’s failure to use some power or
exercise some right that renders cure unavailable.5 
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MERGEFORMAT 36 and keyed text.
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of the scope of seller’s obligation, although in essence being curative in nature and in relation to the prior contractual relations
between the parties, is a matter of general contractual interpretation. Courts would take into consideration the curative context,
but allow that parties have since undertaken a new allocation of performances and risks. Such was the case, e.g., in France 26 April
1995 Cour d 'appel  [Appellate Court] Grenoble (Marques Roque Joachim v. Manin Rivi)re) ,  available online at
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The primary right that aggrieved parties may hold and whose exercise would frustrate any
subsequent attempt to cure is the right to declare the contract avoided.6 Once the contract is
legally avoided there can be no cure.7 Thus a contractual regime may subject the power to avoid
the contract to the right to cure.8 In such cases, the breaching party is immune – at least
temporarily, until the curative period is over and cure fails – from the aggrieved party’s power to
declare the contract avoided. In all other cases, any post-avoidance communication or indeed
curative performance by the breaching party would fail qua cure, amounting to an offer of a new
or modified contract which may or may not excuse past breaches.9 
The following discussion analyzes the relations between cure and avoidance of the contract in the
PECL and CISG on these theoretical lines. Both the CISG and PECL allow for post-breach cure
and both restrict the right to circumstances discussed in detail below; however, while the CISG
allows for cure subject to avoidance of the contract, the PECL makes no such overt, general
qualification. As argued below, contextual considerations both rationalize this discrepancy and
mitigate it.
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 3. Cure for What? 
When analyzing cure mechanisms, two initial questions emerge: What failures of performance
may be cured? Under what restrictions? While the latter question is dealt with in detail below, the
former requires special initial attention. Under CISG Art. 48(1) the seller is allowed to cure “any
failure” to perform his obligations. As scholars comment,10 this is a general provision, which
covers fundamental and non-fundamental breaches alike. Likewise, PECL Art. 8:104 covers all
“tenders of performance” that do not “conform to the contract,” whether the non-conformance be
fundamental or not, as long as the delay in performance itself does not constitute a fundamental
non-performance. The breaching party’s right to cure, then, initially operates independently of the
distinction between fundamental and non-fundamental breaches, on which its inverse right – the
aggrieved party’s right to avoid the contract – hinges. 
However, unlike the CISG, PECL Art. 8:104 restricts the right to cure to those cases in which the
very delay in performance does not constitute a fundamental non-performance. In cases where
“time is of the essence” as the Comment to PECL 8:104 puts it,11 the only way to achieve cure is
through the aggrieved party setting a Nachfrist period; otherwise, the non-performing party has no
right to cure. Indeed, this point requires some clarification: PECL Art. 8:104 sets apart a category
of curative tenders that, while indeed remedying the initial non-performance at the time of the
projected contractual performance – whether fundamental or not (e.g., a non-conformity of goods)
– would, if allowed, constitute a fundamental non-performance at the time of cure. In transactions
in which the time of performance is of the essence, the delay inherently associated with any
curative performance may be such as to constitute a fundamental non-performance, even if the
initial failure of performance was not fundamental and indeed cured. In such cases, the non-
performing party has no right to cure and, accordingly, the aggrieved party has no obligation to
accept cure. In granting the right to cure, Art. 8:104 is indifferent to the question of the
fundamentality of the initial non-performance, but would not allow the curative tender itself to
amount to a fundamental non-performance. Otherwise, the right to cure under Art. 8:104 exists
in all (and only in all) cases where the delay itself – while ad definitio amounting to a non-
performance in relation to the contract – does not constitute a fundamental non-performance. 
In both the CISG and PECL, the crucial question of the relation between the seller’s right to cure
and the buyer’s right to avoid the contract arises; ultimately, that question will determine in what
cases the right to cure may actually take effect as a right rather than a newly-arrived agreement
between the parties. This topic must be analyzed in detail, as follows.
4. The Relation Between Cure and Avoidance (Termination) of the Contract
Both the CISG and PECL must regulate the relations between the seller’s right to cure “any”
failure to perform, and the buyer’s power to declare the contract avoided in certain cases (namely,
fundamental and tantamount breaches). That is because cure and avoidance cannot both occur in
the context of the same contract – it is an absurdity to have a contract both avoided and cured.
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Cure and avoidance compete for positions of relative preeminence in the same normative space,
while each is operated by a different party.12 Granted, a successful curative performance by the
seller – one that adheres to the relevant rules, etc. – cures her breach, ex post; this, however, does
not entail that the seller’s ex-ante right to cure preempts the aggrieved buyer’s power to avoid the
contract. Accordingly, one can identify three theoretical models for relations between the right to
cure and the power to avoid the contract: 
The preemptive model, according to which the right to cure preempts the power to declare the
contract avoided, with the logical corollary that no avoidance can become effective unless proper
opportunity for cure has been allowed;13 
The unconditional model, according to which avoidance of the contract is allowed irrespective of
the availability of cure, and once the contract has been avoided no cure – even when otherwise
available – could take place; 
The independent or “race” model according to which whichever is invoked earlier in time,
whether the right to cure or a declaration of avoidance, becomes effective, rendering the other
unavailable; but no a-priori normative hierarchy is established. 
In the remainder of this section, the three models are invoked in the contexts of the Convention
and the European Principles while remarking on the differences between their approaches as well
as that of the UNIDROIT Principles. As we shall see, both PECL and CISG take the
unconditional model (2) as their general framework while weaving in elements of the independent
model (3) as well.
4.1 Cure for Non-Fundamental Breaches Under CISG
The relation between cure and avoidance of the contract in the CISG has been subject to
considerable controversy within the drafting committee,14 and remains in academic controversy
today. 
Obviously, whether the right to cure is contingent upon the contract not having been avoided is
a major relational characteristic of the contractual framework. However, both PECL and to an
even greater degree the CISG apply a stringent approach to the buyer’s right to avoid the contract
following breach by the seller.15 To wit, declaring the contract avoided is generally reserved – with
one significant exception – to fundamental breaches. This means that the right to cure is
unqualified in the sense defined above in both PECL and CISG for any non-fundamental breach.
Does the latter statement indeed hold? It might be argued that under both PECL and CISG
avoidance of the contract may precede and thus frustrate seller’s attempt to cure even in the cases
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obligation to act in good faith) see Albert H. Kritzer, “Overview Comments on Reasonableness”, available online at
<http://cisgw3.law.pace.edu/cisg/text/reason.html>: “Reasonableness is specifically mentioned in thirty-seven provisions of the
CISG and clearly alluded to elsewhere in the Uniform Sales Law. Reasonableness is a general principle of the CISG.” See also
comments by Jelena Vilus, available online at <http://cisgw3.law.pace.edu/cisg/text/reason.html#vilus>; rpr. in Homenaje a Jorge
Barrera Graf, vol. 2, Mexico: Universidad Nacional Aut4noma de Mexico (1989) 1440-1441. For the definition of reasonableness
recited in the Principles of European Contract Law and references to reasonableness in Continental and Common Law domestic
rules, doctrine and jurisprudence, go to <http://cisgw3.law.pace.edu/cisg/text/reason.html#def>. For further discussion regarding
the correlation between the PECL’s definition of reasonableness and the meaning of this term to CISG legislators when they used
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of some non-fundamental breaches. The issue here is, of course, that dealt with by CISG Art.
49(1)(b), whose proper interpretation engaged several scholarly disputes, and by its counterpart
PECL 8:106(3). Those provisions allow for avoidance of the contract even for non-fundamental
breaches, as long as three conditions are satisfied: 
That the breach in question is one of non-delivery (according to CISG) or delay in performance
(according to PECL); 
That the non-performing party was allowed a reasonable time extension to perform – so-called
Nachfrist period; and 
That he has failed to do so. The non-fundamental breach is then “upgraded” and avoidance of the
contract becomes available. 
On the face of it, this seems to belie the cure doctrine of CISG Art. 48. In fact, however, the two
doctrines sit very well together due to the curative nature of the Nachfrist mechanism. In fact,
whether the buyer allows a curative period on a Nachfrist mechanism such as CISG Art. 47 or
PECL Art. 8:106, or whether the seller invokes cure based on the provisions discussed here, are
two sides of the same coin and probably of little practical importance. Because the requirements
of reasonableness direct both doctrines,16 the curative period in both cases is of the same nature.
4.2 Cure for Non-Fundamental Breaches Under PECL
The first clause of PECL Art. 8:104 simply states the right to cure a non-conforming tender at any
time prior to the designated time for performance; it is therefore the counterpart of CISG Art. 37
rather than Art. 49 and relatively non-controversial. The second clause of Art. 8:104 grants a non-
performing party the right to cure after the designated time to perform has passed (of course,
following the sphere of application of the PECL, in any contractual context and not limited to
sellers). However, unlike the CISG, this right under PECL is limited to cases where the delay
would not amount to a fundamental non-performance. The nature of this limitation is discussed
below in the section devoted to cure; it does not affect the clear rule that, in all cases of non-
fundamental non-performance, the non-performing party maintains a general right to cure.
What is being cured under Art. 8:104? The language here is somewhat peculiar: it is a “tender of
performance” that “does not conform” to the contract. The term “tender performance” appears
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and 9:303 (Notice of Termination). 
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19 See Peter Schlechtriem, “Interpretation, gap-filling and further development of the UN Sales Convention” available online
at <http://cisgw3.law.pace.edu/cisg/biblio/schlechtriem6.html>. 
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delivery”; see Yovel, supra note 3. In other contexts, some legal systems allow defenses against enforcement of negotiable
instruments in cases of completer failure of consideration tendered but not in cases of partial failure, etc.
8
elsewhere in the Principles though infrequently;17 in most cases, to “tender performance” seems
to mean “to perform”, whether the performance conforms to the contract or not. To emphasize
this, the examples given in the PECL Comment on cure include both cases of sales and of
services.18 Art. 8:104 also indicates that cure occurs in cases where the other party refused
“acceptance” of the performance, although parties under PECL generally have no right to reject
non-conforming tender and the so-called “perfect tender” of the UCC § 2-601 is unknown to it.19
The defining words are, therefore, “tender conforming to the contract,” similar to that used in
Art. 9:401 (Right to Reduce Price). What does “non-conformity” of tender to the contract (as
opposed of non-conformity of goods) mean? 
Specifically, is the language of “non-conforming tender” different in any material sense from the
simpler “non-performance” more prevalent in the PECL? 
Is the right to cure under Art. 8:104 reserved to cases where some performance was tendered, as
opposed to total failure to perform? 
There is nothing in the short PECL Comment on cure to indicate such a construction. While
legal regimes sometimes distinguish between complete failure to perform and partial failure,20 and
while one can admit to the logic of allowing for cure in cases of debtors who at least tried and
managed to complete a portion of their obligations, such a distinction is generally reserved to
specific areas of law and is justified by specific contexts. It does not seem correct to make it a core
precept of the general principle of cure. 
Thus, for the time being and until tribunals and cases offer casuistic constructions of Art. 8:104
the conclusion should be that there is no essential difference between “tender non-conforming to
the contract” and “any failure to perform,” the more overt language of the CISG Art. 48(1). 
4.3 Cure for Fundamental Breaches Under CISG
The CISG’s treatment of the relation between cure and avoidance of the contract changes
drastically in respect to fundamental breaches . Under CISG Art. 48(1) the seller is allowed to cure
“any failure” to perform his obligations. On the other hand, under Art. 49(1) the buyer may avoid
the contract where the seller's failure amounts to a fundamental breach, whether the seller offers
to cure or not. 
The relation between the two competing rights is set up in Art. 49(1) where the operative language
makes the seller’s right to cure “subject to Art. 49.” Art. 49 regulates avoidance of the contract
following either fundamental breach or “constructed fundamentality” following failure to perform
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21 For a similar criticism see Christopher Kee, “Commentary on the Manner in which the UNIDROIT Principles May Be Used
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ed. (1999); pp. 320-21, available online at <http://cisgw3.law.pace.edu/cisg/biblio/ho48.html>. With respect, I dispute this
jurisprudential point on the following grounds. Cure is certainly more specific than breach in general, in the sense that the set of
all the cases of cure is a sub-set of all the cases of breach (it is complemented by the set of non-cured breaches). Had avoidance been
available for any breach, the set of all available avoidances would then be identical with the set of all breaches and Honnold’s
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fundamental breach (and even then not to all such cases, as reasonable time limitations render avoidance unavailable in some
cases). There are cases where cure is available but avoidance is not, namely the set of non-fundamental breaches. Hence both the
set of all instances of cure and the set of all rightful avoidances are both independent subsets of the general set of breaches – they
maintain a certain zone of convergence, namely, the set of fundamental breaches that where the contract has not been avoided –
yet none is more or less specific than the other. Indeed, to claim that the set of instances of cure is in some sense a subset of the
set of available avoidances is simply assuming that which is to be determined.
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throughout a Nachfrist period. As the second case in fact allows for cure – initiated by the
aggrieved buyer – the remainder of this section will discuss cure in cases of fundamental breaches.
What does “subject to Art. 49” mean? 
Does it mean that under CISG the seller’s right to cure is qualified, in that in case of fundamental
breach it can be cut off through the buyer’s exercise of his power to declare the contract avoided?
Or does it even indicate that cure is not designated for cases of fundamental breaches at all? 
If either of these is the proper construction of the relation between Arts. 48 and 49, then the right
to cure in cases of fundamental breach under CISG seems limited indeed; it would then also
stand in contrast to the PECL’s much more liberal approach to cure. In the following, I shall argue
that the proper construction of the relation between cure and avoidance of the contract under
PECL in fact allows for cure even in cases of fundamental breach, although in those cases they are
indeed subject to being cut off by the buyer’s exercise of the right to avoid the contract; hence a
qualified right to cure in the terms specified above.
It is worthwhile to note that under UNIDROIT Principles the breaching party’s right to cure is
unequivocally stronger than the aggrieved party’s power to terminate the contract. UNIDROIT
Principles Art. 7.1.4(2) states that “The right to cure is not precluded by notice of termination”;
the Comment adds that “If the aggrieved party has rightfully terminated the contract … the effects
of termination … are also suspended by an effective notice of cure. If the non-performance is
cured, the notice of termination is inoperative.” This is not the place for a comprehensive critique
of this approach; to this commentator, it seems unattractive in the extreme in the sense that
rightful terminations of contracts may posthumously be rendered inoperative, thus introducing
serious uncertainty into the calculations of the aggrieved part who has terminated the contract
rightfully and wishes to move on; it also plays havoc with the conceptual integrity of termination
of contract.21 Nor does the PECL contain a similar provision, as discussed below.
According to Professor Honnold, the seller’s right to cure under Art. 48, being more specific than
the general right to avoid the contract, prevails over the buyer’s right to avoid the contract.22 With
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tests of conformity. As this was not a case of non-delivery, Art. 49(b) could not apply and, if avoidance of the contract was
unavailable, that must have been the cause, not the relations between avoidance of the contract and cure. Furthermore, this case
should be read in the context of CISG Arts. 47 and 48(2), as the seller has communicated to the buyer his intention to cure; the
unavailability of avoidance during the ensuing period follows Art. 48(2), not necessarily an inverse relation between Arts. 48 and
49 to the one argued for above. Additionally, the court held that by sending samples of fabric instead on the curing goods
themselves seller has performed lawfully, as there was no certainty that buyer would accept the substitute goods. To this
commentator, it seems that the court deemed that the seller has performed reasonably and in good faith in attempting to cure the
alleged breach. In itself, however, that cannot change the normative hierarchy between avoidance of the contract (which under
CISG as under PECL is not a matter of fault but one of objective performance) and cure under CISG. Indeed, the fact that the
power to avoid is normally suspended following Art. 48(2) is a logical corollary of that hierarchy; it would be redundant otherwise.
Germany, 24 September 1998 Landgericht [District Court] Regensburg; case presentation including English translation available
online at <http://cisgw3.law.pace.edu/cases/980924g1.html>.
26 Ziegel, supra note _Ref99341181\h \* MERGEFORMAT 2, at 9-21. Such is also Professor Schlechtriem’s opinion, see Peter
Schlechtriem, Uniform Sales Law - The UN-Convention on Contracts for the International Sale of Goods (Manz, Vienna: 1986) pp. 76-77,
available online at <http://cisgw3.law.pace.edu/cisg/biblio/schlechtriem.html>. Professor Schlechtriem adds that this construction
was objected to at the committee by the German delegation that wished to strengthen the right to cure so that it does not become
subject to cut off by avoidance of the contract, but that this approach was not ultimately accepted. For case law where the court
had – among other determinations – accepted the buyer’s effective declaration of avoidance of the contract as putting an end to
the availability of cure by the breaching seller see Italy 24 November 1989 Court of First Instance Parma (Foliopack v. Daniplast),
presentation including English translation available online at <http://cisgw3.law.pace.edu/cases/891124i3.html>.
27 This conclusion is supported by case law. See 
Italy 24 November 1989 Court of First Instance Parma (Foliopack v. Daniplast), CLOUT case No. 90, case presentation
including English translation available at <http://cisgw3.law.pace.edu/cases/891124i3.html>; 
Germany 17 September 1991 Oberlandesgericht [Appellate Court] Frankfurt, CLOUT case No. 2, case presentation including
English translation available at <http://cisgw3.law.pace.edu/cisg/cases/910917g1.html> ; 
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respect, such a construction might hold absent the operative words “subject to Art. 49.” As the
clause stands,23 following a long and tortured legislative history in the drafting committee,24 it
clearly regulates the relationship between cure and avoidance by creating a hierarchy between
them: cure is available only inasmuch as the power to avoid the contract under Art. 49 has not
been rightfully exercised.25 As Professor Ziegel puts it, “no right to cure survived avoidance of the
contract by the buyer.“26 Thus, under terms of CISG Art. 48(1), the buyer’s right to avoid under
Art. 49 is an independent right unaffected by the seller’s intentions to cure. This conclusion is
strengthened by Art. 48(2) that deals with suspension of the buyer’s power to declare the contract
avoided during a curative period requested by the seller: the aggrieved buyer’s communicative act
(including failure to communicate) is necessary for such a suspension. Had the seller’s right to
cure been preemptive in relation to the buyer’s power to avoid the contract, no such
communicative act on behalf of the buyer would be necessary: the buyer would then have been
automatically enjoined from exercising the power to avoid the contract during the period specified
in the seller’s notice (which would not then be a “request” at all) (for discussion see below). Case
law generally supports this conclusion,27 although cases exist in which courts remark, at least in
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Germany 1 February 1995 Oberlandesgericht [Appellate Court] Oldenburg , CLOUT case No. 165, case presentation including
English translation available at <http://cisgw3.law.pace.edu/cisg/cases/950201g1.html> ; 
Germany 25 June 1997 Bundesgerichtshof [Supreme Court], CLOUT case No. 235, case presentation including English
translation available at <http://cisgw3.law.pace.edu/cisg/cases/970625g2.html>; 
ICC Arbitrat ion Case No. 7531 of 1994, CLOUT case No. 304, case presentation available at
<http://cisgw3.law.pace.edu/cisg/cases/947531i1.html>. 
See also Official Records of the United Nations Conference on Contracts for the International Sale of Goods, Vienna, 10 March–11 April
1980 (United Nations publication, Sales No. E.81.IV.3), p. 41. 
28 As well as contra the proper construction of CISG Art. 49 that requires no grace period for performance as a condition for
declaring the contract avoided. 
29 See supra note _Ref99613505\h \* MERGEFORMAT 26; other courts casually argue that “[seller] offered to repair the
defect: [buyer] should have accepted this proposal, instead of seeking avoidance of her contract with the [seller]”, even in cases of
alleged fundamental breach; Switzerland 27 April 1992 District Court Locarno Campagna, case presentation including English
translation available at <http://cisgw3.law.pace.edu/cases/920427s1.html>. Such dicta, in consideration of the above argument,
seem to reflect preferred rather than the applicable law.
30 See supra note _Ref99709183\h \* MERGEFORMAT 12.
31 Termination for non-fundamental delays in performance is also available, following a Nachfrist period set by the buyer (see
PECL Art. 8:106(3)); however, in such cases it is pointless to ask cure is available as the essence of the Nachfrist mechanism is the
granting of a curative period, although set by the buyer rather than by the seller.
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obiter dicta, and contra the analysis presented here,28 that buyer’s right to avoid the contract is in
some manner contingent upon giving the seller a proper opportunity to cure the defect.29
4.4 Cure and Termination Under PECL
As noted above, unlike the CISG, PECL Art. 8:104 restricts the right to cure to those cases in
which the very delay in performance does not constitute a fundamental non-performance. This is
not a matter of competition between the non-performing party’s right to cure and the aggrieved
party’s power to terminate the contract (under PECL Art. 9:301), that would obviously kick in in
such cases. Whether the aggrieved party intends to terminate or not, in cases where “time is of the
essence” as the PECL Comment on Art. 8:104 puts it,30 the only way to achieve cure is through
the aggrieved party setting a Nachfrist period, i.e., suspending its power to terminate the contract
for the duration of the curative period. 
While the CISG, in the opening words of Art. 48(1), sets the relations between cure and
avoidance of the contract, the PECL does not overtly make the right to cure subject to the buyer’s
power to terminate the contract. In the terms discussed above, the right to cure in Art. 8:104,
although limited to the classes of cases discussed above, is general rather than qualified. 
This would seem to indicate a stronger right to cure in the PECL than in the CISG that would
extend to the relation between cure and termination. However, as noted above, Art. 8:104 limits
the right to cure to cases where the delay in performance would not amount to a fundamental non-
performance. Under PECL 9:301, only fundamental non-performances allow the buyer to
terminate the contract.31 It thus follows that the seller has no right to cure in any case where due
to the delay the buyer holds the power to terminate the contract, even if the buyer eventually does
not exercise that power. 
Under PECL Art. 8:104, the question of whether the seller’s right to cure is or is not subject to
the buyer’s power to terminate the contract simply cannot occur in cases where the power to
terminate stems from the very delay associated with the curative tender. 
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What about cases of fundamental non-performance that may be cured without the delay
amounting to fundamental non-performance? Such cases potentially involve two competing
norms: ostensibly, they allow for the non-performing party’s right to cure under Art. 8:104, as well
as for the aggrieved party’s power to terminate the contract under Art. 9:301. What is the relation
between these two norms? 
Had there been no overt solution to this question we would have to move towards jurisprudential
considerations such as offered by Honnold, e.g., examining whether there is some established
solution to a clash of the two norms (such as the application of the more specific over the more
general one), or employ some general framework of risk allocation. In the context of the PECL,
however, interior analysis shows that the power to terminate the contract is generally independent
and effectively not contingent upon the right to cure, as follows.
The general way in which termination of contract in the PECL is executed is through appropriate
notices (see Art. 9:301). It is typical of the PECL that it regulates substantive rights through a
regulation of the corresponding notices.32 Art. 9:303(3)(a), allows the aggrieved party to give a
notice of termination either before or after a late tender – such as cure – has been made; the only
restriction is that for a post-cure notice of termination to be effective it must be given in
reasonable time. This is therefore not merely a procedural rule regarding the proper way to
exchange notices but a regulation of the relations between termination and cure in the PECL.
Under PECL Art. 9:305(1) that governs the effects of termination of contract, “Termination of the
contract releases both parties from their obligation to effect and to receive future performance.”
Cure is obviously a future performance (the language of Art. 8:104 is “tender of performance” but
the semantic difference is meaningless), and so termination of the contract under PECL releases
the aggrieved party from any obligation to receive cure, exactly as its effect is to relinquish her right
to enforce the contract through specific performance.
PECL Art. 9:303(3)(b) mitigates the harshness – for the non-performing party – created by the
strict hierarchy in favor of termination over cure in Art. 9:303(3)(a). It determines that in cases in
which the aggrieved party “knows or has reason to know” of forthcoming cure in reasonable time,
it must notify the curing party of its refusal to accept cure in order to maintain its power to
terminate the contract. Failure to notify the curing party accordingly will render termination of the
contract unavailable and the road to cure open; however, a notice of refusal to accept cure would
keep the power to terminate the contract alive. Even then – unless the refusal to accept cure
includes or is constructed to include a notice of termination of the contract – the right to cure
under Art. 8:104 would still hold. Only a termination of the contract would relieve the aggrieved
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Context,” 10th John Maurice Kelly Memorial Lecture, Dublin 2004, at pp. 38-9.
34 See BGB §§ 437 et seq.
35 BGB § 323(1). That is the general case; there are specific clauses such as § 635 (for contractor’s option to cure). BGB §
323(2) lists several categories of exemptions and scattered clauses add to those (e.g. § 440 and the obvious § 325(5)).
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party from her obligation to accept cure. The conclusion then must be, that the right to curative
performance depends on the contract not having been previously terminated. 
Art. 9:303(3)(b) is a relational protection of the non-performing party’s reliance interests in the
context of curative performance, but it obviously recognizes the aggrieved party’s power to
terminate the contract, which can be rendered ineffective only under the specified circumstances
indicated. Note, that the onus-creating language in PECL Art. 9:303(3)(b) relating to the aggrieved
party “knows or has reason to know” is wider than under the corresponding CISG Art. 48(2) and
(3), according to which the information relating to the forthcoming cure must be communicated
by the breaching party itself. The PECL recognizes that there are instances in which the aggrieved
party should assume that cure is forthcoming, even absent direct communication from the
breaching party to that effect. 
Of course, the aggrieved party’s notification to the non-performing, cure-aspiring party under
9:303(3)(b) may be that it refuses cure and hereby terminates the contract; like under the CISG,
the PECL does not offer non-performing parties a preemptive right to cure in cases of
fundamental and tantamount non-performances (there are no other relevant cases in fact), unless
the aggrieved party assents to accept cure or unreasonably fails to notify the curing party that it
would not accept it.
The analytic conclusion then must be that the power to terminate the contract under PECL –
which exists only in cases of fundamental and tantamount breaches – is independent of any
allowance for cure, except where the aggrieved party’s power becomes suspended under Art.
9:303(3)(b). This differs from the approach of several national legal systems. As Professor
Zimmermann explains it, in German sales law the right to “supplementary performance” is the
aggrieved buyer’s “primary right.”33 Although not spelled out as such,34 termination of the contract
under German law generally becomes available to the aggrieved party following the breaching
party’s failure to cure.35 That is not the approach of either the CISG or the PECL. 
Under PECL, Termination of the contract releases the aggrieved party from the obligation to
accept cure and thus nullifies the non-performing party’s right to cure, which otherwise exists in
relation to both fundamental and non-fundamental non-performances alike (with the exception
of the fundamentality of the delay itself, as discussed above). The aggrieved party is allowed to
terminate the contract even after a curative tender, as long as it does so in reasonable time. Of
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36 Cure obviously becomes available also in cases of non-fundamental non-delivery if the buyer has set a Nachfrist period. Failure
to cure throughout that period makes avoidance of the contract available to the buyer under CISG Art. 49(1)(b).
37 Honnold’s proposal to internalize the offer to cure into the construction of the fundamentality of the breach would have
been a brilliant resolution to the relation between cure and avoidance; unfortunately it was not accepted. See Ziegel, supra note
_Ref99341181\h \* MERGEFORMAT 2, at 9-21. See also Michida, “Cancellation of Contract”, 27 Am.J. Comp. L. 286-288
(1979), available online at <http://cisgw3.law.pace.edu/cisg/biblio/michida.html> Occasionally courts would determine that
willingness to cure may reduce the severance of the breach from fundamental to not-fundamental; see Germany 31 January 1997
Ober landesger icht  [Appel late Court ]  Koblenz,  CLOUT case No. 282, case presentat ion avai lab le  onl ine at
<http://cisgw3.law.pace.edu/cisg/cases/970131g1.html>. This is an attractive relational notion, consistent with the PECL’s
general obligations of good faith and fair dealing; however, I doubt whether it may hold under the CISG’s approach to avoidance
of contract, see Yovel, supra note _Ref99709231\h \* MERGEFORMAT 5. 
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course, a successful cure may frustrate the availability of post-cure termination if the cure – as
successful cure should – renders the non-performance at the time of cure non-fundamental. 
4.5 No Preemptive Cure as Unqualified Right under CISG and PECL
Both the CISG and PECL allow for some measure of preemptive cure, i.e., cure that renders
avoidance of the contract unavailable, whether temporarily or irrevocably. This does not mean,
however, that preemptive cure is given the normative status of right that unilaterally tramps rights
and powers held by the aggrieved party. Under the CISG Art. 48(2), if the aggrieved buyer allows
the seller to cure during the time indicated in his request (whether by assenting or failing to reply),
she is barred from avoiding the contract during that period. Note, however, that the decision
whether to suspend the power to avoid the contract or not remains with the aggrieved buyer: she
may always answer in the negative to a seller’s request. As the seller’s right to cure operates
whether the buyer consents to accept cure or not, the buyer’s refusal to accept cure in itself has no
legal effect other than keeping her power to avoid the contract effective. However – as concluded
above – nor is the buyer’s power to avoid the contract effected merely by the seller’s intention or
efforts to cure. That power becomes available only in cases of fundamental and tantamount
breaches, and we conclude that those are the cases in which Art. 48(2) really matters. 
The question of preemptive cure becomes relevant in cases of fundamental breach, because
otherwise the seller has no right to avoid the contract. Yet the only way in which cure can be
preemptive in those cases is when the buyer agrees in advance to withhold exercising her power to
avoid the contract for an indicated duration; and under both PECL and CISG the buyer’s silence
operates as such an assent to cure. 
4.6 Conclusion
Under the risk-allocating terms of CISG Art. 48(1) (no unreasonable delay, no inconvenience to
buyer, and assumption of costs by seller), the seller holds an unqualified right to cure in all cases
of non-fundamental breach.36 However, the seller’s right to cure in cases of fundamental breach is
qualified in that it may be cut off and become unavailable if the seller rightfully avoids the contract
under Art. 49(1), unless the buyer has assented to accept cure or failed to object to it, which would
result in suspension of her power to avoid the contract under Art. 48(2).37 
Nordic Journal of Commercial Law issue 2005 #1
38 Germany 9 June 1995 Oberlandesgericht [Appellate Court] Hamm, CLOUT case No. 125, case presentation available
including English translation available online at <http://cisgw3.law.pace.edu/cases/950609g1.html> (costs for replacing defective
windows).
39 By analogy because in curing, the seller is not performing an obligation but excersicing a right. The purported gap in Art.
8:104 – the allocation of costs and risks associated with cure – calls for completion by analogy from within the PECL before we
proceed to external sources of construction. 
40 ICC Arbitration Case No. 7754 of January 1995, ICC International Court of Arbitration Bulletin 2000, 46, case presentation
available at <http://cisgw3.law.pace.edu/cases/957754i1.html> (the conditions are satisfied when, e.g., defective motors can easily
be adjusted in due time and at minimal costs).
41 See BGB § 121. German courts acknowledged a possible discrepancy between “reasonable time” and “without unreasonable
delay,” even when the facts happened to satisfy both; see Germany 17 September 1991 Oberlandesgericht [Appellate Court]
Frankfurt, case presentation including English translation available at <http://cisgw3.law.pace.edu/cases/910917g1.html> (in this
case a one-day delay in sending an avoidance telex after the breach was discovered at a trade fair was judged both reasonable and
unverzüglich). In another case, an Italian buyer of a used car was allowed to avoid the contract three months after she discovered the
car was previously stolen and title cannot be transferred; the court accepted the time as pertinent to the various inspections
required. Had the seller attempted to cure, however, it might have been determined that the condition of “without reasonable
delay” could not be met: Germany 22 August 2002 Landgericht [District Court] Freiburg, case presentation including English
translation available at <http://cisgw3.law.pace.edu/cases/020822g1.html>. 
42 E.g. Arts. 1139, 1146.
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Under PECL Art. 1:804, the right to cure is not qualified for either fundamental or non-
fundamental non-performances, although it is limited in cases where time is of the essence, as
discussed above. However, under Art. 9:303(3)(a) the aggrieved party’s power to terminate the
contract is unaffected by later cure as long as the notice of termination is given in reasonable time
after cure was performed. This provides a strong incentive to non-performing parties to
communicate their intention to cure so as to bring about the suspension of the aggrieved party’s
power to terminate the contract under Art. 9:303(3)(b), as otherwise their cure will not operate
preemptively. 
5. Expenses of Cure and Associated Risks
Cure may accrue costs and internalize risks that are not allocated between the parties in the
contract. If any exist, the CISG Art. 48(1) allocates them to the seller.38 As far as the buyer is
concerned, the curative performance is to be as close as possible to the projected contractual
performance. Obviously, any associated costs which would effectively serve to remove or reduce
the seller’s susceptibility to a lawsuit for breach of contract must be borne by the seller. The PECL
is silent on this point, but as this rule seems germane to the logic of cure it must hold under it, as
well. Also, as cure is a substitute performance, PECL Art. 7:112, according to which each party
must bear “the costs of performance of its obligations”, will apply here, by analogy if not directly.39
6. “Without Unreasonable Delay”
There must be a limit to the period during which the aggrieved buyer must accept cure. CISG Art.
48(1) limits cure only to cases where it can be achieved without unreasonable delay.40 This
language, similar to the “unverzüglich” of the BGB [German Civil Code]41 or the “interpellation
suffisante” prevalent in the French Code Civil,42 indicates a relatively shorter period than the
Nordic Journal of Commercial Law issue 2005 #1
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47 See Honnold, 298.
48 See Official Records of the United Nations Conference on Contracts for the International Sale of
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“reasonable time” under which a declaration of avoidance must be given according to CISG Art.
49.43 It is therefore a further application of the general principle of reasonableness that, as
Professor Kritzer has argued, is a general principle of the CISG.44 
In cases where the seller has indicated to the buyer the length of the intended cure period – as
must be the case when the breach is fundamental (under CISG Art. 49(2)) and is prudent also
when it is non-fundamental – that indication, subject to the requirement of reasonableness, will
determine the period for cure. In no case other than when he has explicitly accepted is the buyer
obligated to accept cure later than that.45 
The PECL’s generally stringent approach to delay bears an interesting relation to the parallel
requirement in CISG Art 49(1). PECL Art. 8:104 in fact uses language that appeared in early
drafts of the CISG and was later scrapped for the “unverzüglich” principle.46 In the context of the
PECL, the general obligation to act in good faith and fair dealing (Art. 1:201) governs the
substantial right to cure. It should be added, that in similar contexts the PECL treats delayed
performance more severely than the CISG. For instance, while avoidance of contract for non-
fundamental breaches is available under CISG in cases of non-delivery only (following a Nachfrist
period, see CISG Art. 49(1)(b)), PECL allows avoidance following Nachfrist in the wider category
of cases of non-fundamental delays in performance (see PECL Art. 8:106(3)). 
May there be cure in a time that is longer than “reasonable”? Honnold47 emphasizes, that the
seller’s request according to Art. 48(2) should not necessarily be restricted to the conditions of
cure of Art. 48(1); seller may therefore request to perform cure under different conditions, to
which the buyer may agree or not, but will be held to if she fails to respond to the said request.
What if the seller’s request under Art. 48(2) and (3) does not indicate a time frame for cure?
According to some sources, such an indication is a sine qua non of the request and without it, it
can have no effect.48 To this commentator, this seems too harsh; if the seller does not indicate a
time for cure, the default time indicated in Art. 48(1) – namely, “without reasonable delay” –
would kick in and govern the undertaking to cure. Art 48(2) allows the seller to attempt to divert
from the minimal time requirement, but does not oblige him to do so.
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7. Retaining the Right to Damages
The performance of cure does not obliterate the fact that a contract was breached. Thus, although
the performance of appropriate cure virtually substitutes for that of the original contractual
obligation (hence making both avoidance of the contract and any order for specific performance
inappropriate), it does not preclude an additional order for damages.49 Under CISG Art. 48(1)
these are damages “as provided for in this Convention” i.e., including those damages covered by
Art. 74.50 (A dictum by an Austrian court suggests that while CISG generally provides for reliance
as well as expectation damages for breach of contract, cure generally revokes the availability of the
latter.51 However, one must note that while in cases of successful cure expectation damages will
not be awarded on the merits (that, after all, is what cure is aimed to achieve), it does not follow
that this is the proper construction of the damages clause in Art. 48. Even cure that is identical to
the projected contractual performance in all save the time of performance may fail to compensate
for loss of some of the projected (and foreseeable, etc.) added value to the buyer expected from the
contract. There is no reason to indemnify the seller from liability in such cases. From this
perspective, what cure affords breaching sellers (and to what it subjects aggrieved buyers) is, in fact,
the possibility of mitigating any damages to which the seller would otherwise be liable through
substitute performance. There is no guarantee that the substitute performance will cover the entire
loss to the buyer generated by the breach. 
PECL Art. 8:104 says nothing about damages; however, it does not preclude further damages in
cases of cure and the same logic should apply here. Thus the general PECL clauses that make
damages available to aggrieved buyers would operate here. Cure would not preclude damages,
although it would contribute towards there mitigation, and a perfect performance of cure would
mitigate those damages completely. 
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8. System of Notices
While avoidance is declared, cure is performed. However, declaring the intention to cure (or otherwise
making it known to the aggrieved party, cf. PECL Art. 9:303(3)(b)) may carry with it a legal effect
in the sense of shifting a certain communicative onus to the aggrieved party who wishes to retain
the power to avoid the contract. This is true for both PECL (as discussed cursorily above) and the
CISG, as follows.
While PECL Art. 8:104 does not indicate any special mode for notices of cure exchanged by the
parties – and is thus subject to the regular rules governing communication, set in Art. 1:303, and
indirectly those governing notices of termination in Art 9:303 – the CISG designates an entire
communicative system to govern the establishment of cure, Art. 48(2), (3) and (4). This system
governs, however, more than merely the ways in which notices in the context of cure are to be
exchanged between the parties, as it regulates some of the substantive rights of the parties
contingent on their communicative behavior.
Under both CISG and PECL (and unlike under the UNIDROIT Principles), cure may be
exercised without notice to the aggrieved buyer.52 CISG Art. 48(2), however, discusses the case in
which the seller “requests” the buyer’s approval of the seller’s intended cure.53 (Literally, the
relevant language is “accept[ing] performance”, by the buyer, a slightly awkward wording within
the context of the CISG which does not operate under the perfect tender rule and thus buyers
have no right to reject performance other than by avoiding the contract).54 
There are two separate operations involved here. In case of non-fundamental breach, the seller is
not so much “requesting” anything as much as giving notice of cure - it is not a request because
the buyer has no right to refuse. The operation of the request is much more significant under
conditions of fundamental breach. As under such conditions the buyer retains the right to avoid
the contract, the seller in fact offers to cure the breach under condition that the buyer forebear
from exercising her right to declare the contract avoided. The buyer may, of course, refuse the
offer to cure and exercise her power to avoid the contract (or not avoid it, as the case might be,
and resort instead to other remedies, such as damages). But if she agrees to “accept” cure, or
simply fails to respond to the request within a reasonable time, she will become estopped from
exercising her right to avoid the contract or reducing the price for the duration indicated in the
request. Note that this is an exception to the general rule of the CISG Art. 18(1) according to
which “Silence or inactivity does not in itself amount to acceptance.” 
Nordic Journal of Commercial Law issue 2005 #1
55 Seller must then allow “reasonable time” for the buyer to answer. See Finland 12 November 1997 Turku Court of Appeal,
case presentation including English translation available at <http://cisgw3.law.pace.edu/cases/971112f5.html>. See also when a
communication “reaches” an addressee, CISG Art. 24.
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The harshness of this rule is mitigated by Art. 48(4) according to which a request according to Art.
48(2) becomes effective upon receipt by the buyer (itself an exception to the general rule in Art. 27
where it suffices to dispatch the notice).55 Of course, whether a breach is fundamental or not may
be controversial; the buyer herself may be unsure of the availability of avoidance, the seller unsure
whether she holds a right to cure. Art. 48(2) provides a strong incentive to the cautious seller to
communicate with the buyer and sort this out. There is no prejudice to the seller for if the breach
is non-fundamental than she retains to right to cure whatever the buyer’s response may be. Yet it
would prevent the situation of a seller engaging in costly cure while buyer intends to declare the
contract avoided. The “race” between cure and avoidance is thus best resolved through application
of CISG Art. 49(2).
